What is stem cell therapy?
Stem cell therapy is the administration of stem or progenitor cells — autologous or allogeneic, unmodified or genetically modified — to replace, repair or modulate a tissue. This page summarises the registered clinical a
Stem cell therapy is the administration of stem cells or their progenitor derivatives to a recipient, either autologous (donor and recipient the same individual) or allogeneic, with the aim of replacing, repairing, or modulating a damaged tissue. The term covers several distinct product classes: mesenchymal stem/stromal cells (MSCs), haematopoietic stem and progenitor cells (HSPCs), and neural crest-derived stem cells, among others. Products may be unmodified or genetically modified ex vivo before infusion. Because the field spans multiple cell types and indications, no single molecular formula, sequence, or molecular weight identifies "stem cell therapy" as a substance; identity is defined operationally by cell phenotype, source tissue, expansion protocol, and route of administration.
The mechanistic work in this record centres on mitochondrial oxidative phosphorylation (OXPHOS) as a determinant of MSC functional fate, and on lentiviral-vector-mediated gene addition to autologous HSPCs [5][2].
Research Studies
MSCs and non-viral acute-on-chronic liver failure (Phase II)
A Phase II trial sponsored by the National Collaborative Centre for Hepatic Regenerative Medicine (NC-CHRM) is evaluating MSC therapy in patients with non-viral acute-on-chronic liver failure (ACLF) [1]. The stated rationale is the gap between demand for liver transplantation in India — over 100,000 procedures needed annually against roughly 2,500 performed — and the absence of validated non-transplant options. The programme is designed to develop and validate MSC-based therapy intended to promote native liver regeneration [1].
Gene-modified HSPCs and transfusion-dependent beta-thalassemia (Phase IIb)
A prospective, dual-centre, single-dose, single-arm, open-label Phase IIb study is testing autologous HSPCs genetically modified with the GLOBE lentiviral vector under an improved transduction protocol in nine patients with transfusion-dependent beta-thalassemia [2]. The protocol defines four study phases, beginning with screening to assess inclusion and exclusion criteria after informed consent, with recruitment from two participating sites [2].
MSCs and premature ovarian failure
A registered study evaluates the therapeutic potential of autologous MSC therapy in women with premature ovarian failure (POF) [4]. The stated purpose is to assess therapeutic potential in this population; the record does not report efficacy outcomes.
Stem cell therapy as a comparator context in knee osteoarthritis
A trial of pulsed electromagnetic field (PEMF) therapy in patients with knee osteoarthritis (OA) situates stem cell therapy within the wider regenerative-technology landscape [3]. The record notes that knee OA prevalence exceeds 40% in the elderly in Hong Kong, that no cure exists, and that pharmacological and regenerative options including stem cell therapy are being developed but are expensive per se, with side effects not uncommon [3]. Stem cell therapy is not the intervention under test in that study.
Mitochondrial-targeted nano-enhancer and MSC spheroid metabolism in bone regeneration
Preclinical work reports that mitochondrial OXPHOS plays a crucial role in determining the functional fate of MSCs, and that strategies to precisely modulate mitochondrial bioenergetics within three-dimensional MSC spheroids to improve bone repair remain limited [5]. The study describes a mitochondrial-targeted nano-enhancer driving a self-amplifying NAD+ feedback loop to reprogram MSC spheroid metabolism for accelerated bone regeneration [5]. This is in vitro / spheroid-level work, not a clinical finding.
Hair follicle-derived neural crest stem cells and neural hearing loss
In an ouabain-induced spiral ganglion neuron injury model in rats, cochlear nerve surface transplantation of hair follicle-derived neural crest stem cells was associated with partial hearing recovery [6]. The authors frame effective cell delivery as a critical challenge for sensorineural hearing loss (SNHL) treatment and established the injury model to address it [6]. This is an animal model; no human hearing outcome is reported.
Adipose-derived stem cells and cavernous nerve injury
In a rat model of cavernous nerve injury, adipose-derived stem cell (ASC) therapy restored erectile function and promoted recruitment of endogenous stem cells [7]. The study was designed to investigate the therapeutic effects of exogenous stem cells and their recruitment of endogenous cells, noting that erectile dysfunction following non-nerve-sparing prostatectomy is prevalent and that the underlying mechanisms of ASC action remained unclear [7]. This is animal-model evidence.
Comparison of the registered clinical programmes
| Programme | Cell type | Modification | Population | Phase / model |
|---|---|---|---|---|
| NC-CHRM ACLF trial [1] | MSC | Unmodified | Non-viral ACLF patients | Phase II |
| Beta-thalassemia trial [2] | Autologous HSPC | GLOBE lentiviral vector | Transfusion-dependent beta-thalassemia (n=9) | Phase IIb |
| POF study [4] | Autologous MSC | Unmodified | Women with premature ovarian failure | Registered study |
| PEMF knee OA trial [3] | Not applicable | Not applicable | Knee OA patients | Stem cell therapy referenced as context only |
Where the evidence sits
- Human clinical: registered interventional studies in ACLF, transfusion-dependent beta-thalassemia, and premature ovarian failure [1][2][4].
- Animal model: rat cavernous nerve injury and rat ouabain-induced spiral ganglion injury [7][6].
- In vitro / spheroid: mitochondrial-targeted nano-enhancer work in 3D MSC spheroids [5].
Claims of tissue repair or functional restoration should be read against the model in which they were observed. Findings in rat models and in MSC spheroids do not establish human clinical effect.
If you are reading this for personal health reasons
The materials described on this page are supplied for laboratory research use only. We do not provide dosing information, treatment protocols, or medical guidance of any kind. Anyone considering a stem cell-based intervention for themselves should consult a licensed clinician.
Sources
- [1] National Collaborative Centre for Hepatic Regenerative Medicine (NC-CHRM): Evaluating Mesenchymal Stem Cell Therapy in Non-viral Acute on Chronic Liver Failure (ACLF) Patient — Phase-II Trial. https://clinicaltrials.gov/study/NCT07131306
- [2] Gene-Modified Stem Cell Therapy for Subjects With Transfusion-dependent Beta-thalassemia. https://clinicaltrials.gov/study/NCT07680803
- [3] The Effect of PEMF for Patients With Knee OA. https://clinicaltrials.gov/study/NCT05548712
- [4] "It is a Real" The First Baby Of Autologous Stem Cell Therapy in Premature Ovarian Failure. https://clinicaltrials.gov/study/NCT02372474
- [5] Mitochondrial-targeted nano-enhancer driving a self-amplifying NAD+ feedback loop to reprogram MSC spheroids metabolism for accelerated bone regeneration. https://pubmed.ncbi.nlm.nih.gov/42497772/
- [6] Partial hearing recovery after cochlear nerve surface transplantation of hair follicle-derived neural crest stem cells in neural hearing loss rat. https://europepmc.org/article/PMC/PMC13394508
- [7] Adipose-derived stem cell therapy restores erectile function and promotes endogenous stem cell recruitment in a rat model of cavernous nerve injury. https://pubmed.ncbi.nlm.nih.gov/40954197/